- Home
- GILD vs BSX Comparison
GILD vs BSX Comparison
Compare GILD & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- BSX
- Stock Information
- Founded
- GILD 1987
- BSX 1979
- Country
- GILD United States
- BSX United States
- Employees
- GILD N/A
- BSX N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- BSX Medical/Dental Instruments
- Sector
- GILD Health Care
- BSX Health Care
- Exchange
- GILD Nasdaq
- BSX Nasdaq
- Market Cap
- GILD 144.1B
- BSX 157.6B
- IPO Year
- GILD 1992
- BSX 1992
- Fundamental
- Price
- GILD $115.05
- BSX $107.22
- Analyst Decision
- GILD Buy
- BSX Strong Buy
- Analyst Count
- GILD 23
- BSX 22
- Target Price
- GILD $115.68
- BSX $118.32
- AVG Volume (30 Days)
- GILD 5.9M
- BSX 6.0M
- Earning Date
- GILD 11-05-2025
- BSX 10-22-2025
- Dividend Yield
- GILD 2.75%
- BSX N/A
- EPS Growth
- GILD 496.80
- BSX 36.90
- EPS
- GILD 5.01
- BSX 1.68
- Revenue
- GILD $28,863,000,000.00
- BSX $18,494,000,000.00
- Revenue This Year
- GILD $2.01
- BSX $19.75
- Revenue Next Year
- GILD $4.03
- BSX $10.98
- P/E Ratio
- GILD $22.96
- BSX $63.82
- Revenue Growth
- GILD 3.81
- BSX 21.44
- 52 Week Low
- GILD $77.74
- BSX $80.50
- 52 Week High
- GILD $121.83
- BSX $108.94
- Technical
- Relative Strength Index (RSI)
- GILD 52.20
- BSX 59.36
- Support Level
- GILD $111.28
- BSX $104.24
- Resistance Level
- GILD $118.13
- BSX $108.47
- Average True Range (ATR)
- GILD 2.06
- BSX 1.59
- MACD
- GILD -0.46
- BSX 0.26
- Stochastic Oscillator
- GILD 39.23
- BSX 80.53
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About BSX Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.